The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Metastasis is responsible for 90 percent of cancer deaths. Researchers have found that the mutations driving it may stem from a commonly inherited variant of the PCSK9 gene.

New research suggests elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves ...

When mice are engineered to carry a variant of the human PCSK9 gene, they experience higher rates of breast cancer metastasis ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

In fact, Tavazoie and colleagues had previously demonstrated that various germline alleles of APOE can enhance or suppress melanoma metastasis. To find out whether breast cancer metastasis operates in ...

HDL is reduced. PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

PubMed and Scopus databases were searched to retrieve clinical trials on the efficacy and/or safety of novel LDL-C-lowering agents including PCSK9 inhibitors, mipomersen (Kynmaro®), lomitapide ...